Cargando…

Phase I study of combination therapy with weekly paclitaxel and cyclophosphatamide for advanced or recurrent breast cancer

Detalles Bibliográficos
Autores principales:	Nakayama, T, Masuda, N, Yamamura, J, Kamigaki, S, Taguchi, T, Hatta, M, Sakamoto, J
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2009
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4284903/ http://dx.doi.org/10.1186/bcr2300

Ejemplares similares

Phase I study of weekly paclitaxel in combination with pazopanib and lapatinib in advanced solid malignancies
por: Tan, A R, et al.
Publicado: (2014)

A Phase I study of NLG919 for adult patients with recurrent advanced solid tumors
por: Nayak, Asha, et al.
Publicado: (2014)

Phase I study of lurbinectedin in combination with weekly paclitaxel with or without bevacizumab in patients with advanced solid tumors
por: Calvo, Emiliano, et al.
Publicado: (2022)

Phase I study of alpha-tocopherlyoxyacetic acid in patients with advanced cancer
por: Curti, Brendan D, et al.
Publicado: (2015)

Phase I/II study of cisplatin combined with weekly paclitaxel in patients with advanced non-small-cell lung cancer
por: Yoshimura, N, et al.
Publicado: (2004)

Phase I/II study of S-1 combined with paclitaxel in patients with unresectable and/or recurrent advanced gastric cancer
por: Mochiki, E, et al.
Publicado: (2006)

Prognostic value of a high level of circulating endothelial cells in patients with HER2-recurrent or metastatic breast cancer treated with bevacizumab in combination with paclitaxel and gemcitabine as first-line therapy
por: Manso, L, et al.
Publicado: (2011)

Weekly Paclitaxel Versus Three-Weekly Paclitaxel in Recurrent Platinum-Resistant Epithelial Ovarian and Peritoneal Cancers: A Phase III Study
por: Osman, Mohammed A., et al.
Publicado: (2016)

A Phase I study to evaluate the safety and antitumor activity of durvalumab (MEDI4736) in combination with tremelimumab in patients with advanced solid tumors
por: Papadopoulos, Kyriakos P, et al.
Publicado: (2015)

Phase II Study of S-1 Monotherapy as a First-line, Combination Therapy of S-1 plus Cisplatin as a Second-line, and Weekly Paclitaxel Monotherapy as a Third-line Therapy in Patients with Advanced Gastric Carcinoma: Phase II Study of S-1, S-1 plus Cisplatin, and Weekly Paclitaxel in Patients with Advanced Gastric Carcinoma
por: Rino, Yasushi, et al.
Publicado: (2008)

Phase sequences in balanced recurrent networks
por: Chenkov, Nikolay, et al.
Publicado: (2013)

Phase I/II study of nivolumab with or without ipilimumab for treatment of recurrent small cell lung cancer (SCLC): CA209-032
por: Taylor, Matthew, et al.
Publicado: (2015)

ZD6474 in combination with paclitaxel and UVB irradiation enhances the antiproliferative effect and apoptosis on breast carcinoma
por: Sarkar, S, et al.
Publicado: (2009)

Phase I/II study of ADXS11-001 or MEDI4736 immunotherapies alone and in combination, in patients with recurrent/metastatic cervical or human papillomavirus (HPV)-positive head and neck cancer
por: Cohen, Ezra EW, et al.
Publicado: (2015)

CITN-06: a Phase I/expansion trial of alt-803, an IL-15 superagonist, in patients with advanced melanoma
por: Margolin, Kim, et al.
Publicado: (2014)

CD8+ T cell stimulation with pegylated recombinant human IL-10 in the patient with advanced solid tumors - a Phase I study
por: Naing, Aung, et al.
Publicado: (2015)

Dynamic analysis of recurrent phase patterns in spontaneous human EEG
por: Kim, Won Sup, et al.
Publicado: (2013)

Immune biomarker correlates from a Phase II study of ipilimumab (IPI) with carboplatin and paclitaxel (CP) in patients with unresectable stage III or IV metastatic melanoma (MM)
por: Lapointe, Réjean, et al.
Publicado: (2015)

Randomised phase II study comparing dose-escalated weekly paclitaxel vs standard-dose weekly paclitaxel for patients with previously treated advanced gastric cancer
por: Shitara, K, et al.
Publicado: (2014)

A phase I study of an agonist anti-CD27 human antibody (CDX-1127) in patients with advanced hematologic malignancies or solid tumors
por: Burris, Howard, et al.
Publicado: (2013)

A phase I study of an agonist anti-CD27 human antibody (CDX-1127) in patients with advanced hematologic malignancies or solid tumors
por: Ansell, Stephen, et al.
Publicado: (2013)

Phase I/II storm study: Intravenous delivery of a novel oncolytic immunotherapy agent, Coxsackievirus A21, in advanced cancer patients
por: Pandha, Hardev, et al.
Publicado: (2015)

Phase II study of bi-weekly administration of paclitaxel and cisplatin in patients with advanced oesophageal cancer
por: Polee, M B, et al.
Publicado: (2002)

miR-433 overexpression attenuates the spindle assembly checkpoint response to paclitaxel
por: Furlong, F, et al.
Publicado: (2010)

Phase Ib/II study to evaluate the safety and antitumor activity of durvalumab (MEDI4736) and tremelimumab as monotherapy or in combination, in patients with recurrent or metastatic gastric/gastroesophageal junction adenocarcinoma
por: Kelly, Ronan J, et al.
Publicado: (2015)

Phase I study of axitinib combined with paclitaxel, docetaxel or capecitabine in patients with advanced solid tumours
por: Martin, L P, et al.
Publicado: (2012)

Phase II study of weekly paclitaxel and capecitabine in patients with metastatic or recurrent esophageal squamous cell carcinoma
por: Yun, Tak, et al.
Publicado: (2011)

Utilization of iPad in the system of emergency demand and acceptance
por: Yamada, K, et al.
Publicado: (2012)

Phase Ib Dose-Finding Study of Varlitinib Combined with Weekly Paclitaxel With or Without Carboplatin ± Trastuzumab in Advanced Solid Tumors
por: Lee, Matilda Xinwei, et al.
Publicado: (2022)

Is there a requirement for advanced airway management for trauma patients in the pre-hospital phase of care?
por: Lockey, David J, et al.
Publicado: (2014)

A phase II trial of concurrent chemoradiotherapy with weekly paclitaxel and carboplatin in advanced oesophageal carcinoma
por: Xia, Yi, et al.
Publicado: (2018)

Five advanced pancreatic cancer patients in a Phase I study of anti-CD3 x anti-EGFR bispecific antibody armed activated T cells (BATS)
por: Lum, Lawrence G, et al.
Publicado: (2015)

A randomized Phase III trial of weekly or 3-weekly doses of nab-paclitaxel versus weekly doses of Cremophor-based paclitaxel in patients with previously treated advanced gastric cancer (ABSOLUTE Trial)
por: Koizumi, Wasaburo, et al.
Publicado: (2015)

Nanoparticulate paclitaxel loaded into sterically stabilized mixed phospholipid micelles to improve chemotherapy of breast cancer
por: Rubinstein, I, et al.
Publicado: (2005)

Bifurcation structure of phase locked modes in Type I excitable cells based on phase and spike time resetting curves
por: Oprisan, Sorinel A
Publicado: (2012)

A phase II randomized trial comparing radiotherapy with concurrent weekly cisplatin or weekly paclitaxel in patients with advanced cervical cancer
por: Geara, Fady B, et al.
Publicado: (2010)

P01-04. Investigation of the sensitivity of acute-phase HIV-1 isolates to type I interferons
por: Dibben, O, et al.
Publicado: (2009)

Understanding the pathophysiology of NOMID arthropathy for drug discovery by iPSCs technology
por: Nakagawa, K, et al.
Publicado: (2015)

Phase I study of metformin in combination with carboplatin/paclitaxel chemotherapy in patients with advanced epithelial ovarian cancer
por: Broekman, K. Esther, et al.
Publicado: (2020)

A Phase I study of AD5-GUCY2C-PADRE in stage I and II colon cancer patients
por: Snook, Adam, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_g86g2393a68aot1ba9t685vuls